65,437 trials
Osteoarthritis, Knee
Primary: Change From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee — -2.84; -3.17 score on a scale — p=0.1904
Fistulizing Crohn's Disease
Primary: Percentage of Participants Who Achieved Combined Fistula Response at Week 24 — 47.1; 29.2; 25.0 percentage of participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab — 9.66; 9.97 micrograms per milliliter (ug/mL)
Airway Management During Operative Procedure
Primary: Duration of Use Under Clinical Anesthesia of Each Absorbent — 1931; 1806; 1527 min
Arteritis, Giant Cell
Primary: Adverse Events — 93 percentage of subjects
Head and Neck Cancer
Primary: Number of Participants With SAEs — 3 Number of Participants
COVID-19
Primary: Time-Weighted Average Daily Change From Day 1 in Viral Load in NP Swab Samples — -1.68; -2.25; -2.34; -2.24 log10 copies/mL — p=0.0004
Ankylosing Spondylitis
Primary: The Proportion of Participants Who Achieved Inactive Disease Based on the Ankylosing Spondylitis Disease Activity Score (ASDAS) Measure — 9; 7 Participants
Relapsed/Refractory Acute Myeloid Leukemia
Primary: Count of Patients With Treatment-Emergent Adverse Events (Phase 1) — 6 Participants
Covid19 · Anosmia · Fever
Primary: Number of Subjects With COVID-19 Symptoms at Day 3. — 93; 90; 9; 13 Participants — p=0.3849
Brain Metastases, Adult
Primary: Number of Participants Who Live Longer Than Predicted According to the Graded Prognostic Assessment (GPA) Score — 22 Participants
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
LC Pelvic Fracture
Primary: Posttreatment Pain — 5.3; 6.2; 4.2; 5.6 scores on a scale
Esophageal Cancer · Squamous Cell Esophagus Cancer · Adenocarcinoma Esophagus
Primary: Overall Response Rate (ORR) — 0.08 proportion of participant
HIV/AIDS · Adherence
Primary: Enacted Adherence as Measured by Electronic Monitoring at 6 and 24 Months — 40.2; 36.8; 27.0; 26.6 percentage of adherence